Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration approved Loxoprofen Sodium Cataplasms for marketing, according to a Friday filing with the Hong Kong bourse.
The drug has anti-inflammatory and analgesic qualities and is used for treating diseases and symptoms, including osteoarthritis, muscle pain, and swelling and pain due to injuries, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.